Japan’s Oncolys, Taiwan’s Medigen Team For Telomelysin Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Oncolys BioPharma and the Taiwanese biotech Medigen Biotechnology have formed a partnership to develop Oncolys's Telomelysin cancer drug for Asian markets. The drug is a genetically modified form of the adenovirus that thrives only in cancer cells. Telomelysin is undergoing U.S. clinical trials as a treatment for tongue and esophageal cancers. Under the partnership, Medigen is to conduct Taiwan tests on the drug for treating liver cancer. (Click here for more - a subscription may be required
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.